GENERAL TERMS AND CONDITIONS OF USELire en Français
iBionext SAS – “Société par actions simplifiée” established under French law, with a capital of EUR 250,000, registered under no. : Paris B 813 577 079.
iBionext SAS is accredited by the French Financial Markets Authority (AMF) under #GP-15000031.
Registered office: 74 rue du Faubourg Saint Antoine, 75012, Paris – Phone: +33 1 76 21 47 50
Managing editor: Bernard Gilly
This website is hosted by: SCALEWAY, 8 rue de la Ville l’Evêque, 75008 Paris, France.
Mail: SCALEWAY SAS BP 438 75366 PARIS CEDEX 08 FRANCE , Telephone: +33 (0)1 84 13 00 00
Website updated on: 09/22/2015
General terms and conditions of use
The connection to the website available at the following address www.ibionext.com (the “Website”) implies acceptance of these general terms and conditions of use (the “Terms”).
iBionext SAS may in its entire discretion modify and update these Terms at any time, it being specified that the updated version of these Terms will be effective upon its online release. Users are responsible to visit regularly the Website for updates.
Protection of personal data
iBionext SAS undertakes to protect the privacy of users and the confidentiality of their personal data while using the Website.
iBionext SAS may collect the users’ personal data in order to provide them with the services they requested, answer their queries or send them newsletters. The personal data collected and processed by iBionext SAS through the Website is not sold, rented or made available, free of charge or for a consideration, to third parties. In accordance with French Act n°78-17 of 6 January 1978 on Information Technology, Data Files and Civil Liberties, users have a right to access and to rectify their personal data. In addition, users are also entitled, on legitimate grounds, to object on the processing by iBionext SAS of any personal data relating to them. Those rights may be exercised in writing at firstname.lastname@example.org or at the following address: iBionext – 74, rue du Faubourg Saint-Antoine
75012 Paris, France.
iBionext SAS draws the users’ attention to the fact that for statistical purposes, as a mean to evaluate incoming and outgoing traffic on the Website, some information such as the web browser used or the IP address of users may be recorded by its servers on an anonymous basis through the tools AWStats and Google Analytics. Thus, iBionext SAS does not process any personal data.
Intellectual property rights
All information included in the Website, in particular trademarks, logos, domain names, databases, software, contents (photographs, text, slogans, designs, images, and animated sequences with or without sound, etc.) as well as any intellectual creations incorporated into the Website are the property of iBionext SAS or their respective owners that allowed iBionext SAS to use them. The Terms do not in any way constitute an assignment of the intellectual property rights included in the Website.
Any reproduction, representation, exploitation, creation of derivative works, translation, adaptation or modification, by any process and on any medium whatsoever, without the prior written consent of iBionext SAS is strictly prohibited and may be punished under counterfeiting laws.
The information on this Website is intended for the users’ personal use only and cannot be reproduced or communicated to third parties, in full or in part, for commercial or non-commercial purposes.
In accordance with Articles 318-10-1 of the General Regulations of the Autorité des Marchés Financiers and AMF instruction N° 2012-07 as amended on 16 October 2014, iBionext has developed an efficient and transparent procedure for the reasonnable and prompt handling of complaints from clients.
A claim is defined as a declaration of client / carrier dissatisfaction with the professional. A request for information, advice, clarification, service or service is not a complaint. The transmission of the complaints is made by mail with acknowledgment to the following address : iBionext 74 rue du Faubourg Saint Antoine, 75012 PARIS
iBionext ensureshat the claims processing phase is carried out with promptness and loyalty towards its customers and commits itself :
-acknowledge receipt of any complaint within 10 working days, by any means. A reply to the complaint within this timeframe waives iBionext to acknowledge receipt of the complaint.
-to reply to any complaint within a maximum of 2 months, except in the event of special circumstances duly justified.
iBionext itself don’t have an internal mediation service. However, if the answer is not satisfactory, it is possible to contact the AMF Mediation : AMF Mediator, Ms Marielle Cohen-Branche, 17 Place de la Bourse – 75002 PARIS Cedex 02
The AMF mediation request form and the mediation charter are available on the website http://www.amf-france.org
Conflict of Interest
iBionext has formalized a policy for the management of conflicts of interest and has put in place specific organizational (means and procedures) and control provisions in order to comply with the European MIF Directive (Market for Financial Instruments).
To prevent, identify and manage conflict of interest situations that may affect the interests of its clients.
As such, it is recalled that iBionext attaches the utmost importance to the interests of its customers.
Thus, iBionext is authorized according to situations of conflicts of interest to : – Carry out the activity or the operation insofar as the organization makes it possible to manage in an appropriate way the situation of potential conflicts of interest. – inform the client in the event that certain conflicts of interest may exist and provide him with the necessary information on their nature and origin.
The Conflict of Interest Policy is available on request.
Compliance with regulation and business ethics
The Website is operated by iBionext SAS, whose registered office is in France, and the Terms are governed by French law.
The laws and regulations of the country from which the user accesses the Website may contain restrictions on the distribution of the web-posted material. In this case, material from the Website may not be distributed or used by any individual or legal entity. Such individual or legal entity must be aware of and comply with such regulations. The purpose of this Website is to present the activities of iBionext SAS and provide information on its products. This presentation cannot be considered as canvassing. The information contained on this Website has no contractual value. This information does not, under any circumstances, constitute a product offer, a recommendation and/or solicitation of purchase offer, or a public offering.
The information available on iBionext SAS Website is provided for information purposes only and is valid at the time of posting. This information may nevertheless be incomplete, owing to the necessarily simplified nature of the content, and is not contractually binding. It does not constitute an investment recommendation or advice specifically directed or in response to the specific needs of the Website’s users.
Any investment entails a degree of risk. As a consequence, and prior to any investment decision, users must read and understand the relevant applicable regulatory accompanying documents of such investment.
iBionext SAS draws the attention of users that past performance is not a guarantee for future performance and that investments valuation may fluctuate up or down. As a consequence, investors may not be able to recover their initial investment and are not entitled to claim any guaranteed income from such investment.
iBionext ensures that the development of new technology solutions in HealthTech integrates extra-financial objectives of sustainable development (environmental, social and governance). The iBionext operating model facilitates the optimization of resources and creates synergies by virtue of its flexibility and the pooling and sharing of space and support functions.
As a member of the France Invest Association, iBionext has signed the investors for growth charter. iBionext is also a signatory of the United Nations’ Principles for Responsible Investment.
As a true partner, iBionext is constantly working on strengthening the ESG aspects by actively dialoguing with companies on the importance of integrating these new non-financial issues into their business and operations.
Environmental – Pooling and sharing resources & facilities
iBionext and the start-ups of its ecosystem take part in basic actions to preserve the environment, such as sharing human expertise, grouping companies, sharing common spaces and maintenance services, dematerialization and computer archiving. The grouping of start-ups at the same location in the center of Paris reduces carbon footprint and avoids any transportation costs of the management team to attend board of directors and other committee meetings. In addition, video conferences help maintain relationships with the founders and international research institutes in the network.
The environmental actions are followed by all portfolio companies (recycling, selection of ESG compliant business partners, waste management, etc.).
Social – A major patient impact
The HealthTech start-ups of the ecosystem have the potential to bring a real benefit to society.
iBionext’s mission is to cure or manage diseases with huge unmet medical needs affecting millions of patients worldwide. iBionext’s goal is to bring to the bedside of patients, new drugs, services and medical devices that will help to improve the quality of life of patients and caregivers and alleviate costs for public and private payers. iBionext has implemented a patent strategy in order to protect these innovative technologies and allow the companies to transform scientific discoveries into viable products on the HealthTech market.
The team places human capital at the forefront of all its investment decisions, without which no value creation would be possible. iBionext’s start-ups are driving the abundant potential of French research. The entrepreneurial model allows to offer jobs to young students, hire qualified researchers or bring back experienced international managers to France. iBionext’s unique feature of creating a centered ecosystem, makes it easy for teams to share a common vision with over 300 highly qualified jobs created since inception, including 35+ nationalities, and an constantly improving male/female ratio (55% vs. 45%). The quality of the management and its involvement in the investment project are key elements of success.
Governance – Nurturing and valuing human capital
iBionext’s governance creates value: as a co-founder, iBionext contributes to bringing the best practices in corporate governance to align the interests of all parties and prevent conflicts. As a lead investor from the first stages up until the exit, iBionext ensures a continuum in strategy through board membership. The iBionext team is an active and operational shareholder, working alongside the managers and providing them with best tools to which it has access: network of companies, sector experts, advice, bank financing, international support etc…
An ESG clause is integrated to shareholders’ agreements of the invested companies. iBionext ensures a follow-up of its ESG policy by setting up reports available to its investors.
Liability and disclaimers
The Website is presented by iBionext SAS “as is”, and iBionext SAS shall not be held responsible for the quality, completeness, or availability of the Website. In particular, because of the inherent limits of the Internet network, iBionext SAS does not guarantee a continued access to the Website, without interruption or errors, and cannot be held responsible for the difficulties or the impossibility to use the Website.
Despite the care exercised by iBionext SAS, technical errors may occur. These may arise, for example, as a result of limited access or incorrect transmission of information, or be due either to the Website itself, or to the intervention of third parties. iBionext SAS cannot be held liable for any loss or damage arising therefrom, and undertakes only to take remedial actions once the fault has been reported.
In addition, users acknowledge that for maintenance or update purposes, the access to the Website may be temporarily suspended.
iBionext SAS is responsible for updating the Website. iBionext SAS has made its best efforts to ensure the accuracy of the information posted but cannot be held liable for any loss or damage of any kind that might arise from the explicit or implied opinions or information posted on the Website.
iBionext SAS cannot be held liable for any direct or indirect loss or damage, particularly material damage, loss of data, or financial loss, as a result of connecting to or using the Website or from reliance on information available on the Website.
iBionext SAS shall make its best efforts to secure access to the Website, but cannot ensure absolute security. iBionext SAS cannot be held liable for damage arising from unauthorized intrusion by a third party that alters the information posted on the Website, or from dysfunctions or damages inherent to the use of the Internet network, such as service failure, computer viruses, or computer security breaches that may cause damages to users’ terminals or data.
The Website may contain hypertext links to other Internet websites published by third parties. To the extent that iBionext SAS does not control those websites, iBionext SAS does not make any representation relating to such websites and cannot be held liable in any manner for the contents, operation and access to such websites.
Links to the iBionext SAS’ Website are not permitted without the prior written consent of iBionext SAS.
Integration of sustainability risk (art. 5 SFDR)
At this stage, iBionext’s remuneration policy does not include sustainability risks. However, the nature of the criteria to be taken into account in order to integrate these risks is currently being considered. The sustainability criteria defined will be integrated into the employee remuneration policy for the next annual objectives setting campaign.
Applicable law – Disputes
These Terms are governed by French law. Any dispute relating to their interpretation or application of shall be settled by the Paris courts.